A DIVERSIFIED CANNABIS COMPANY
Emerald Health Sciences (EHS) is a diversified cannabis company positioned to take advantage of the significant projected growth in different segments of the cannabis industry.
The target segments are Pharmaceuticals, Botanicals (Medical and Recreational), and Bioceuticals. Each investment leverages the scientific rigor, federal regulatory compliance, and life-science expertise of Emerald Health Sciences’ leadership.
Investing in multiple industry segments
EMERALD HEALTH PHARMACEUTICALS (EHP)
Is developing two proprietary molecules derived from Cannabidiol (CBD) and Cannabigerol (CBG) for the treatment of Multiple Sclerosis and Scleroderma.
EMERALD HEALTH BOTANICALS (EHB)
Produces and sells cannabis and oils under federal license from Health Canada.
EMERALD HEALTH BIOCEUTICALS (EHBio)
Develops proprietary formulations that stimulate the Endocannabinoid system for sale in the U.S.
Preparing for the World’s Largest Legal Market for Recreational Cannabis
Canada’s current government has promised to legalize and regulate recreational cannabis and to introduce new legislation to that end in spring 2017. EHB is gearing up its production in preparation for the potential explosive growth in the market when cannabis is legalized in Canada.
Meet our team
Emerald Health Sciences’ management integrates extensive experience in building successful life-science companies, industry-leading scientific expertise, and compliance with all applicable international and federal legislation to develop new drugs and products.
Leadership in Cannabis Science
The world’s top researchers in cannabinoid science are guiding Emerald Health’s Drug Discovery and Drug Development programs.
Emerald Milestones & News
Track Emerald’s and get the latest Emerald News.